Maze Therapeutics, Inc. (MAZE)

NASDAQ: MAZE · Real-Time Price · USD

27.33

+0.41 (1.52%)

At close: Aug 3, 2026, 4:00 PM EDT

28.10

+0.77 (2.82%)

Pre-market: Aug 4, 2026, 4:00 AM EDT

Maze Therapeutics Financials Overview

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Revenue	-	-	167.5	-	-
Revenue Growth	-	-	-	-	-
Gross Profit	-	-	167.5	-	-
Operating Income	-134.05	-142.9	57.59	-98.55	-111.03
Net Income	-122.54	-131.12	3.41	-100.42	-114.94
Earnings Per Share	-2.53	-3.05	1.25	-43.89	-57.21
EPS Growth	-	-	-	-	-

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Investments	352.38	341.92	196.81	29.16	99.92
Total Debt	61.22	23.31	26.63	49.62	32.06
Net Cash (Debt)	291.16	318.61	170.18	-20.47	67.86
Net Cash Growth	8.42%	87.22%	-	-	-
Net Cash Per Share	5.92	7.41	62.33	-8.94	33.78

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Operating Cash Flow	-39.11	-111.94	75.95	-86.83	-99.2
Capital Expenditures	-0.59	-0.79	-1.15	-0.44	-1.97
Free Cash Flow	-39.7	-112.73	74.81	-87.27	-101.17
Free Cash Flow Growth	-	-	-	-	-

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Gross Margin	-	-	100.00%	-	-
Operating Margin	-	-	34.38%	-	-
Pretax Margin	-	-	31.88%	-	-
Profit Margin	-	-	31.18%	-	-
FCF Margin	-	-	44.66%	-	-

Selected indicators aren't available for this stock.